BeijngFH Health Cohort Study

Recruiting

• Conditions: Non-Alcoholic Fatty Liver Disease

• Registration Number: NCT05546086
• Lead Sponsor: Beijing Friendship Hospital

Brief Summary

Metabolic associated fatty liver disease(MEFLD) is a major chronic liver disease that can lead to various adverse events, such as liver cancer, cardiovascular disease, and chronic kidney disease. The present community-based cohort study enrolls subjects who take health physical examinations at the sub-center outpatient department, Beijing Friendship Hospital. Investigators collect their baseline information, including demographic data, clinical history, physical examination, laboratory results, imageological examination, and so on. Follow-up surveys are conducted annually and the information collected is the same as the baseline. The outcome information, including cardiovascular disease, malignancy, liver cirrhosis, liver decompensation, liver transplantation, and all-cause mortality, are obtained by linking to the hospital discharge database and death registration system of Beijing. The primary aim of the study is to build a risk-stratified evaluation system for MAFLD through the cohort.

Detailed Description

The present community-based cohort study enrolls subjects who take physical health examinations at the sub-center outpatient department, Beijing Friendship Hospital. After signing the informed consent, Their previous health physical examination results, which were recorded in the Hospital Information System (HIS) are collected retrospectively. Then, Investigators collect their baseline information, including demographic data, clinical history, physical examination, laboratory results, image logical examination, and so on. Additionally, follow-up surveys will be conducted annually and the information collected is the same as the baseline. The outcome information, including cardiovascular disease, malignancy, liver cirrhosis, liver decompensation, liver transplantation, and all-cause mortality, is obtained from the hospital discharge database and death registration system in Beijing. The study's primary aim is to build a risk-stratified evaluation system for MAFLD through a community population cohort with long-term stable follow-up.

Study Timeline

• Study Start: 2022-04-18
• Status Verified: 2022-09
• Study First Submitted: 2022-09-15
• Study First Submitted QC: 2022-09-15
• Last Update Submitted: 2022-09-18
• Study First Posted: 2022-09-19
• Last Update Posted: 2022-09-21
• Primary Completion: 2032-04-18
• Study Completion: 2032-04-18

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 8103

Inclusion Criteria

• Aged 18 years or older
• Permanent residents in Beijing
• Signing informed consent

Exclusion Criteria

• No

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Cardiovascular disease	1 to 10 years	Incidence of cardiovascular disease during follow-ups

Secondary Outcome Measures

Name	Time	Method
All-cause mortality	1 to 10 years	Incidence of all-cause mortality during follow-ups
Malignancy	1 to 10 years	Incidence of malignancy during follow-ups
Liver cirrhosis	1 to 10 years	Incidence of liver cirrhosis during follow-ups
Liver decompensation	1 to 10 years	Incidence of liver decompensation during follow-ups
Liver transplantation	1 to 10 years	Incidence of liver transplantation during follow-ups

Trial Locations

Locations (1)

Beijing Friendship Hospital, Capital Medical University; 🇨🇳 Beijing, China